Grant: Collaborative Research and Development Grants
McGill University
$147,330.00
Massively parallel linearization and chemical treatment of DNA molecules using tunable nanoscale confinement
FY 2015-16
Summary
Genetic analysis, such as DNA sequencing, has become an established technology for health science research, as well as disease prognosis and diagnosis. However, modern sequencing methods face considerable challenges, presenting key technology development opportunities. For instance, BCC Research expects the global sequencing market to grow to nearly $11.7 billion by 2018 and register an annual growth rate of 21.2% from 2013 to 2018. The technology underlying today's sequencing market dominant shareholder, Illumina, relies on breaking DNA into millions of tiny pieces, many orders of magnitude smaller than the genome. This fracturing process typically leads to a costly and error-prone process of reassembling the genome, and loss of long-range genomic information such as haplotype phase, copy number variation, and structural rearrangements that occur in cancer. Competing long-molecule technologies, as exemplified by Pacific Biosciences, are plagued by high error rates that render their results computationally impractical to use beyond niche applications. The aim of this proposal is to research, develop, and synthesize new technologies to sequence longer DNA strands than current technology and with lower error rates. We combine key expertise in nanoscale physics and single-molecule microscopy, microelectromechanical systems (MEMS) engineering, and labeling chemistry. This proposal kickstarts a relationship between three world-experts: the Leslie Laboratory at McGill University has pioneered novel single-molecule manipulation and visualization ""CLiC"" technology critical to gently untangling, linearizing and analyzing long DNA strands; Micralyne is a leading microfluidics and MEMS foundry in Canada, with extensive fabrication expertise key to miniaturizing Leslie's techniques; ZSGenetics has developed chemical processing approaches to label DNA base pairs for sensitive readout. The resources, training, insights and technologies delivered by this project would train high-quality personnel for growing the biotechnology sector in Canada, generating employment and revenue e.g. fabrication of consumables associated with the technology would be anchored in Micralyne (Edmonton, Canada).
Program
Collaborative Research and Development Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
478302-2015
Name nom
Leslie, Sabrina
Department département
Physics
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
147330
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Massively parallel linearization and chemical treatment of DNA molecules using tunable nanoscale confinement
Keyword
NSERC
Application summary
Genetic analysis, such as DNA sequencing, has become an established technology for health science research, as well as disease prognosis and diagnosis. However, modern sequencing methods face considerable challenges, presenting key technology development opportunities. For instance, BCC Research expects the global sequencing market to grow to nearly $11.7 billion by 2018 and register an annual growth rate of 21.2% from 2013 to 2018. The technology underlying today's sequencing market dominant shareholder, Illumina, relies on breaking DNA into millions of tiny pieces, many orders of magnitude smaller than the genome. This fracturing process typically leads to a costly and error-prone process of reassembling the genome, and loss of long-range genomic information such as haplotype phase, copy number variation, and structural rearrangements that occur in cancer. Competing long-molecule technologies, as exemplified by Pacific Biosciences, are plagued by high error rates that render their results computationally impractical to use beyond niche applications. The aim of this proposal is to research, develop, and synthesize new technologies to sequence longer DNA strands than current technology and with lower error rates. We combine key expertise in nanoscale physics and single-molecule microscopy, microelectromechanical systems (MEMS) engineering, and labeling chemistry. This proposal kickstarts a relationship between three world-experts: the Leslie Laboratory at McGill University has pioneered novel single-molecule manipulation and visualization ""CLiC"" technology critical to gently untangling, linearizing and analyzing long DNA strands; Micralyne is a leading microfluidics and MEMS foundry in Canada, with extensive fabrication expertise key to miniaturizing Leslie's techniques; ZSGenetics has developed chemical processing approaches to label DNA base pairs for sensitive readout. The resources, training, insights and technologies delivered by this project would train high-quality personnel for growing the biotechnology sector in Canada, generating employment and revenue e.g. fabrication of consumables associated with the technology would be anchored in Micralyne (Edmonton, Canada).